ADMA Biologics, Inc. (ADMA) financial statements and ratios from SEC XBRL: revenue $510.17M (TTM), net margin 28.8%, revenue growth 19.6% YoY, P/E 13.7. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $510.17M |
| Net Margin | 28.8% |
| Revenue Growth (YoY) | 19.6% |
| EPS Growth (YoY) | -27.1% |
| FCF Growth (YoY) | -74.8% |
| P/E Ratio | 13.7 |
| EV / EBITDA | 10.2 |
| Price / Book | 5.54 |
| Price / Sales | 4.64 |
| FCF Yield | 8.3% |
| DCF Value (model) | $25.59 |
| DCF Upside vs Price | 162.2% |
| Altman Z-Score | 11.72 (safe) |
| Piotroski F-Score | 5/9 |
| Sector P/E (Healthcare) | 21.6 |
ADMA overview · ADMA earnings · ADMA KPIs · ADMA investor relations · ADMA ownership · ADMA peers · ADMA filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.